(Q37599672)

21 August 2017

1 reference

title

Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms (English)

1 reference

21 August 2017

1 reference

Wasif Riaz

1

1 reference

21 August 2017

Francisco J Hernandez-Ilizaliturri

series ordinal

2

1 reference

21 August 2017

Myron S Czuczman

series ordinal

3

1 reference

21 August 2017

publication date

1 March 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

46

1 reference

21 August 2017

issue

1-3

1 reference

21 August 2017

page(s)

192-205

1 reference

https://scigraph.springernature.com/pub.10.1007/s12026-009-8121-x

21 August 2017

exact match

0 references

cites work

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

https://api.crossref.org/works/10.1007%2FS12026-009-8121-X

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-009-8121-X

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-009-8121-X

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-009-8121-X

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

21 January 2018

1 reference

12 December 2020

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

1 reference

12 December 2020

Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation

1 reference

12 December 2020

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

1 reference

12 December 2020

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

12 December 2020

T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

1 reference

12 December 2020

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

12 December 2020

The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms

1 reference

12 December 2020

Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity

1 reference

12 December 2020

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

1 reference

12 December 2020

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

12 December 2020

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

1 reference

12 December 2020

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

1 reference

12 December 2020

Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma

1 reference

12 December 2020

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.

1 reference

12 December 2020

Cancer statistics, 2009

1 reference

12 December 2020

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

1 reference

12 December 2020

A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.

1 reference

12 December 2020

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density

1 reference

12 December 2020

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

12 December 2020

Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes

1 reference

12 December 2020

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

1 reference

12 December 2020

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

1 reference

12 December 2020

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

1 reference

12 December 2020

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils

1 reference

12 December 2020

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

1 reference

12 December 2020

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgki

1 reference

12 December 2020

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

12 December 2020

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients

1 reference

12 December 2020

Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.

1 reference

12 December 2020

Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics

1 reference

12 December 2020

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

12 December 2020

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

12 December 2020

Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies

1 reference

12 December 2020

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model

1 reference

12 December 2020

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

1 reference

12 December 2020

In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

1 reference

12 December 2020

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

1 reference

12 December 2020

Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model

1 reference

12 December 2020

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

12 December 2020

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

1 reference

12 December 2020

Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2

1 reference

12 December 2020

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Angiostatic activity of the antitumor cytokine interleukin-21.

1 reference

12 December 2020

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab

1 reference

12 December 2020

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

1 reference

12 December 2020

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

1 reference

12 December 2020

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

1 reference

12 December 2020

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

1 reference

12 December 2020

The association between CD20 and Src-family Tyrosine kinases requires an additional factor

1 reference

12 December 2020

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.

1 reference

12 December 2020

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study

1 reference

12 December 2020

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

12 December 2020

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

1 reference

12 December 2020

FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.

1 reference

12 December 2020

From bench top to bedside

1 reference

12 December 2020

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

12 December 2020

Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality.

1 reference

12 December 2020

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

1 reference

12 December 2020

Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.

1 reference

12 December 2020

Caspase-independent killing of Burkitt lymphoma cell lines by rituximab

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies

1 reference

12 December 2020

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

1 reference

12 December 2020

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

12 December 2020

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

12 December 2020

10.1007/S12026-009-8121-X

Identifiers

DOI

1 reference

21 August 2017

1 reference